// App-Quantinova.ai

16477 : Sacubitril/valsartan as a Treatment for Resistant Hypertension in Patients With Heart Failure and Preserved Ejection Fraction

Researchers

Presenter

  • Pardeep S Jhund

Principal Investigators

  • Alice M

  • Marc A Pfeffer

  • Faiez ZANNAD

  • Martin P Lefkowitz

  • Victor SHI

  • Orly Vardeny

  • Scott Solomon

  • John J McMurray

Medical Centers

  • UNIVERSITY OF GLASGOW, Glasgow

  • University of Glasgow, Glasgow, United Kingdom

  • BRIGHAM AND WOMENS HOSPITAL, Boston, MA

  • Cntr d'Investigation Clinique, VANDOEUVRE LES NANCY, France

  • Novartis Pharmaceutical Corporation, East Hanover, NJ

  • NOVARTIS PHARMACEUTICALSCORPORATION, East Hanover, NJ

  • University of Minnesota, Minneapolis, MN

  • Brigham & Women's Hospital, Boston, MA

  • BHF CARDIOVASCULAR RESEARCH CENTRE, Glasgow

Locations

  • United Kingdom

  • United States

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Hypertension

  • Congestive heart failure

  • Diabetes

Biomarkers

  • N/A

Drug/Treatment

  • Sacubitril/valsartan

Outcome

  • N/A

Study Design

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved